- Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
- Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
- Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
- Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
- Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update
- Relief Therapeutics Announces Executive Leadership Team Change
- Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
- Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board
- Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023
- Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting
More ▼
Key statistics
On Tuesday, Relief Therapeutics Holding SA (RLF:SWX) closed at 3.42, 3.48% above its 52-week low of 3.30, set on Jun 05, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.36 |
---|---|
High | 3.69 |
Low | 3.36 |
Bid | -- |
Offer | -- |
Previous close | 3.42 |
Average volume | 21.36k |
---|---|
Shares outstanding | 14.04m |
Free float | 13.10m |
P/E (TTM) | -- |
Market cap | 48.44m CHF |
EPS (TTM) | -4.81 CHF |
Data delayed at least 15 minutes, as of Jun 06 2023 16:31 BST.
More ▼